Ultragenyx Q2 revenue rises 28% to record high, net loss narrows
RARE•Outlook
- Ultragenyx reaffirms 2026 total revenue guidance of $730 mln to $760 mln
- Company maintains 2026 Crysvita revenue outlook at $500 mln to $520 mln
- Ultragenyx expects 2026 combined R&D and SG&A expenses to be flat to slightly down vs 2025
Overview
- US biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company history
- Net loss for Q2 narrowed yr/yr, with loss per share improving to $0.90 from $1.17
- Company reaffirmed 2026 revenue guidance and expects profitability in 2027
Result Drivers
- Crysvita sales and royalties - Q2 Crysvita revenue reached $156 mln, with company citing expected seasonality in US/Canada and ordering patterns in Latin America
- Evkeeza demand - Q2 Evkeeza revenue was $21 mln, driven by increased demand from new country launches and early access
- - Dojolvi launched in Japan in Q2 after approval, contributing to in revenue
Related News
Kodak swings to GAAP profit of $17 million in Q2 FY26; revenue rises 18% to $311 million
KODK•
Suja Life Q2 net loss widens to $27.8 million; net sales rise 11.6% to $83.9 million
SUJA•
